Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.Current Opinion articles that place interesting areas in perspective.Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
靶向肿瘤学通过提供肿瘤学中分子靶向药物治疗的文章计划，向致力于肿瘤学和癌症研究的医生和科学家提供地址。该杂志包括：关于分子靶向药物治疗癌症的所有方面的原创研究文章，包括免疫检查点抑制剂和相关方法;讨论相关临床已确立以及新兴药物和途径的综合叙述性综述文章和较短的主导文章;将感兴趣的领域置于视角的当前观点文章;提供最佳治疗条件指南并强调实际、临床相关考虑和建议的实践中的治疗文章;使用PRISMA声明概述的明确、系统方法的系统综述;对肿瘤学中新的和已确立的靶向药物的性质和治疗位置的Adis药物综述。
PARP Inhibition in Cancer: An Update on Clinical Development
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00680-2
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00631-x
Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00660-6
Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00674-0
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00635-7
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00658-0
Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00645-5
Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00653-5
A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00661-5
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00644-6
High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00689-7
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00675-z
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00643-7
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00630-y
Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00662-4
Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00636-6
Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00622-y
Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00673-1
Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00626-8
The Role of Checkpoint Inhibitors in Glioblastoma
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00655-3
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00665-1
Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00651-7
Rucaparib: A Review in Ovarian Cancer
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00629-5
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00679-9
Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00625-9
Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00652-6
Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00663-3
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00686-w
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00619-7
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00647-3
Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00684-y
Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00637-5
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00657-1
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00628-6
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00666-0
Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX)
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00667-z
BI 853520, a FAK-Simile of Prior FAK Inhibitors?
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00621-z
Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00668-y
A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00654-4
Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00642-8
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00683-z
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00646-4
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00678-w
Correction to: Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00677-x
Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00649-1
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00692-y
Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00682-0
Acknowledgement to Referees
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00687-9
Authors’ Reply to Yu: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00640-w
Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study
来源期刊：Targeted OncologyDOI：10.1007/s11523-019-00691-z
